Pharma News Articles

▼ Show details

MDLinx Pharma helps physicians and healthcare professionals stay up to date with the latest pharma news articles and research, as well as pharma jobs, conferences, and resources.

Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults Full Text Bristol Myers-Squibb, January 30, 2015

2 U.S. FDA approves IMBRUVICA (ibrutinib) for the treatment of Waldenström's Macroglobulinemia: First FDA-approved therapy for this disease Full Text Johnson & Johnson, January 30, 2015

3 Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma Dermatology, January 30, 2015    Clinical Article

4 Posterior augmented glenoid designs preserve more bone in biconcave glenoids Journal of Shoulder and Elbow Surgery, January 30, 2015    Clinical Article

5 Performance of porous tantalum vs. titanium cup in total hip arthroplasty: Randomized trial with minimum 10-year follow-up Journal of Arthroplasty, January 30, 2015    Clinical Article

6 Results of total knee arthroplasty with NexGen LPS-Flex for osteoarthritis in the valgus knee: A study of 26 patients followed for a minimum of 2 years European Journal of Orthopaedic Surgery & Traumatology, January 30, 2015    Clinical Article

7 VP of Business Development appointed to Expand Rayence Product portfolio Imaging Economics, January 30, 2015

8 Bristol-Myers Squibb appoints Giovanni Caforio, M.D., Chief Executive Officer, effective May 5; Lamberto Andreotti to become Chairman Full Text Bristol Myers-Squibb, January 30, 2015

9 Efficacy of antifibrinolytics on surgical bleeding in spine surgery: A meta-analysis The Spine Journal, January 30, 2015    Review Article

10 Cytokinetics to announce fourth quarter results on February 12, 2015 Full Text Cytokinetics, January 30, 2015

11 Biogen Idec 2014 revenues increase 40% to $9.7 billion Biogen Idec, January 30, 2015

12 ARIAD to webcast conference call on fourth quarter and year-end 2014 financial results Full Text ARIAD Pharmaceuticals, January 30, 2015

13 Baxter's fourth quarter financial results exceed expectations Full Text Baxter, January 30, 2015

14 Celldex Therapeutics and Bristol Myers-Squibb announce initiation of phase 1/2 combination study of varlilumab and Opdivo in advanced refractory solid tumors Full Text Bristol Myers-Squibb, January 30, 2015

15 Abbott reports fourth-quarter 2014 results Abbott, January 30, 2015

16 Early ultrasonographic evaluation of idiopathic clubfeet treated with manipulations, casts, and Botox®: A double-blind randomized control trial Journal of Children's Orthopaedics, January 30, 2015    Clinical Article

17 Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH initiative to improve diagnosis and care for people with familial hypercholesterolemia Full Text Amgen, January 30, 2015

18 Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Announce Global collaboration to develop gene therapies for hemophilia Biogen Idec, January 30, 2015

19 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. initiate two phase 3 clinical trials on Charleston's lead product, CL-108 Full Text Daiichi Sankyo, January 30, 2015

20 Trend, risk factors and costs of Clostridium difficile infections in vascular surgery Annals of Vascular Surgery, January 30, 2015    Review Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 NextLast
Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Other Topics in Pharma News

Looking for a physician job? Let us help!

Register now for our free job placement service.
A career consultant will contact you soon.
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List